Skip to main content
All lobbying filings

Bavarian Nordic Inc.

Bavarian Nordic Inc. filed a Q4 report for Bavarian Nordic Inc. on January 23, 2026.

Lobbying for Bavarian Nordic Inc.

As filed: BAVARIAN NORDIC INC. for BAVARIAN NORDIC INC.

All filings by Bavarian Nordic Inc. · Everything Bavarian Nordic Inc. has reported

 Filing · LD-2 quarterly report Q4 report
Reporting period
4th Quarter 2025
Oct 1 - Dec 31 · Posted Jan 23, 2026
Expenses
$130,000
What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.
Client based in
North Carolina

Official filing document

 Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 7

Biodefense; Biomedical Advanced Research and Development Authority funding; vaccine research, development, manufacturing and marketing; infectious diseases; PAHPA; Labor-HHS-ED appropriations bills; NDAA

Biodefense; Biomedical Advanced Research and Development Authority funding; vaccine research, development, manufacturing and marketing; infectious diseases; PAHPA; Labor-HHS-ED appropriations bills; NDAA

Biodefense; Biomedical Advanced Research and Development Authority funding; vaccine research, development, manufacturing and marketing; infectious diseases; PAHPA; Labor-HHS-ED appropriations bills; NDAA

Biodefense; Biomedical Advanced Research and Development Authority funding; vaccine research, development, manufacturing and marketing; infectious diseases; PAHPA; Labor-HHS-ED appropriations bills; NDAA

Biodefense; Biomedical Advanced Research and Development Authority funding; vaccine research, development, manufacturing and marketing; infectious diseases; PAHPA; Labor-HHS-ED appropriations bills; NDAA

Biodefense; Biomedical Advanced Research and Development Authority funding; vaccine research, development, manufacturing and marketing; infectious diseases; PAHPA; Labor-HHS-ED appropriations bills; NDAA

Biodefense; Biomedical Advanced Research and Development Authority funding; vaccine research, development, manufacturing and marketing; infectious diseases; PAHPA; Labor-HHS-ED appropriations bills; NDAA

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem